These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23408996)

  • 41. CLN3p impacts galactosylceramide transport, raft morphology, and lipid content.
    Rusyn E; Mousallem T; Persaud-Sawin DA; Miller S; Boustany RM
    Pediatr Res; 2008 Jun; 63(6):625-31. PubMed ID: 18317235
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Gemfibrozil, food and drug administration-approved lipid-lowering drug, increases longevity in mouse model of late infantile neuronal ceroid lipofuscinosis.
    Ghosh A; Rangasamy SB; Modi KK; Pahan K
    J Neurochem; 2017 May; 141(3):423-435. PubMed ID: 28199020
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The neuronal ceroid-lipofuscinoses.
    Goebel HH
    Semin Pediatr Neurol; 1996 Dec; 3(4):270-8. PubMed ID: 8969009
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Elevated lysosomal pH in neuronal ceroid lipofuscinoses (NCLs).
    Holopainen JM; Saarikoski J; Kinnunen PK; Järvelä I
    Eur J Biochem; 2001 Nov; 268(22):5851-6. PubMed ID: 11722572
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Specific alterations in levels of mannose 6-phosphorylated glycoproteins in different neuronal ceroid lipofuscinoses.
    Sleat DE; Sohar I; Pullarkat PS; Lobel P; Pullarkat RK
    Biochem J; 1998 Sep; 334 ( Pt 3)(Pt 3):547-51. PubMed ID: 9729460
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Current Insights in Elucidation of Possible Molecular Mechanisms of the Juvenile Form of Batten Disease.
    Shematorova EK; Shpakovski GV
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33137890
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses.
    Wisniewski KE; Zhong N; Philippart M
    Neurology; 2001 Aug; 57(4):576-81. PubMed ID: 11548735
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Specific delay in the degradation of mitochondrial ATP synthase subunit c in late infantile neuronal ceroid lipofuscinosis is derived from cellular proteolytic dysfunction rather than structural alteration of subunit c.
    Ezaki J; Wolfe LS; Kominami E
    J Neurochem; 1996 Oct; 67(4):1677-87. PubMed ID: 8858953
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Defect of proteolysis of mitochondrial ATP synthase subunit C in neuronal ceroid lipofuscinosis.
    Ezaki J; Wolfe LS; Kominami E
    Gerontology; 1995; 41 Suppl 2():259-69. PubMed ID: 8821337
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Role of subunit-9 of mitochondrial ATP synthase in Batten disease.
    Johnson DW; Speier S; Qian WH; Lane S; Cook A; Suzuki K; Daniel P; Boustany RM
    Am J Med Genet; 1995 Jun; 57(2):350-60. PubMed ID: 7668362
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An Australasian diagnostic service for the neuronal ceroid lipofuscinoses.
    Muller VJ; Paton BC; Fietz MJ
    Eur J Paediatr Neurol; 2001; 5 Suppl A():197-201. PubMed ID: 11588997
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Loci for classical and a variant late infantile neuronal ceroid lipofuscinosis map to chromosomes 11p15 and 15q21-23.
    Sharp JD; Wheeler RB; Lake BD; Savukoski M; Järvelä IE; Peltonen L; Gardiner RM; Williams RE
    Hum Mol Genet; 1997 Apr; 6(4):591-5. PubMed ID: 9097964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lysosomal protein thermal stability does not correlate with cellular half-life: global observations and a case study of tripeptidyl-peptidase 1.
    Collier AM; Nemtsova Y; Kuber N; Banach-Petrosky W; Modak A; Sleat DE; Nanda V; Lobel P
    Biochem J; 2020 Feb; 477(3):727-745. PubMed ID: 31957806
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease.
    Lukacs Z; Nickel M; Murko S; Nieves Cobos P; Schulz A; Santer R; Kohlschütter A
    Clin Chim Acta; 2019 May; 492():69-71. PubMed ID: 30771299
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Gemfibrozil and fenofibrate, Food and Drug Administration-approved lipid-lowering drugs, up-regulate tripeptidyl-peptidase 1 in brain cells via peroxisome proliferator-activated receptor α: implications for late infantile Batten disease therapy.
    Ghosh A; Corbett GT; Gonzalez FJ; Pahan K
    J Biol Chem; 2012 Nov; 287(46):38922-35. PubMed ID: 22989886
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mouse gene knockout models for the CLN2 and CLN3 forms of ceroid lipofuscinosis.
    Katz ML; Johnson GS
    Eur J Paediatr Neurol; 2001; 5 Suppl A():109-14. PubMed ID: 11588979
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CLN3 protein regulates lysosomal pH and alters intracellular processing of Alzheimer's amyloid-beta protein precursor and cathepsin D in human cells.
    Golabek AA; Kida E; Walus M; Kaczmarski W; Michalewski M; Wisniewski KE
    Mol Genet Metab; 2000 Jul; 70(3):203-13. PubMed ID: 10924275
    [TBL] [Abstract][Full Text] [Related]  

  • 58. CLN2/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype.
    Bessa C; Teixeira CA; Dias A; Alves M; Rocha S; Lacerda L; Loureiro L; Guimarães A; Ribeiro MG
    Mol Genet Metab; 2008 Jan; 93(1):66-73. PubMed ID: 17959406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Batten disease (Neuronal ceroid lipofuscinoses)--accumulation of ATP synthase subunit c caused by the delay of lysosomal degradation].
    Ezaki J; Kominami E
    Nihon Rinsho; 1995 Dec; 53(12):3055-61. PubMed ID: 8577058
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The intracellular location and function of proteins of neuronal ceroid lipofuscinoses.
    Ezaki J; Kominami E
    Brain Pathol; 2004 Jan; 14(1):77-85. PubMed ID: 14997940
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.